Gamida Cell Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gamida Cell Ltd.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are 12 new oncology products developed to treat hematological malignancies that, if successful at the regulators, are due to be launched for the first time next year.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.
The Novartis-backed company will begin a rolling submission to the US FDA for its cord blood-derived cell therapy omidubicel in Q4 based on improved engraftment versus standard cord blood.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Drug Discovery Tools